SHAREHOLDER ALERT: Levi & Korsinsky Launches an Investigation into Possible
Breaches of Fiduciary Duty by Abiomed, Inc.
NEW YORK -- January 17, 2013
Levi & Korsinsky is investigating potential claims on behalf of purchasers of
Abiomed, Inc. (“Abiomed” or the “Company”) (NYSE: ABMD). A complaint was filed
in Massachusetts federal court.
For more information, click here: http://zlk.9nl.com/abiomed-abmd.
The complaint alleges that Abiomed made materially misleading statements
regarding the Company’s financial strength and prospects. In particular, it is
alleged that positive statements concerning the Company were misleading
because the United States Food and Drug Administration ("FDA") repeatedly
warned Abiomed that its promotional materials contained inappropriate claims
regarding its Impella 2.5 catheter and suggested improper off-label uses.
Abiomed repeatedly assured investors that they had addressed the FDA’s
concerns and that the matter was resolved.
On November 1, 2012, Abiomed disclosed that the Department of Justice had
initiated an investigation “focused on the Company’s marketing and labeling of
the Impella 2.5.” On this news, shares of Abiomed’s stock fell from $19.82 per
share on October 31, 2012 to close at $13.61 on November 1, 2012.
If you own Abiomed shares and wish to obtain additional information, contact
Joseph E. Levi, Esq. either via email at email@example.com or by telephone at
(877) 363-5972, or visit http://zlk.9nl.com/abiomed-abmd.
Levi & Korsinsky is a national firm with offices in New York and Washington
D.C. The firm has extensive expertise in prosecuting securities litigation
involving financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results do
not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
Toll Free: 877-363-5972
Press spacebar to pause and continue. Press esc to stop.